A citation-based method for searching scientific literature

Danielle Golub, Nishanth Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Aram S Modrek, Dimitris G Placantonakis. Front Oncol 2019
Times Cited: 95



Fang Wang, Jeremy Travins, Byron DeLaBarre, Virginie Penard-Lacronique, Stefanie Schalm, Erica Hansen, Kimberly Straley, Andrew Kernytsky, Wei Liu, Camelia Gliser, Hua Yang, Stefan Gross, Erin Artin, Veronique Saada, Elena Mylonas, Cyril Quivoron, Janeta Popovici-Muller, Jeffrey O Saunders, Francesco G Salituro, Shunqi Yan, Stuart Murray, Wentao Wei, Yi Gao, Lenny Dang, Marion Dorsch, Sam Agresta, David P Schenkein, Scott A Biller, Shinsan M Su, Stephane de Botton, Katharine E Yen. Science 2013
Times Cited: 542




List of shared articles



Times cited

Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer.
Jinxiu Guo, Ruyue Zhang, Zhe Yang, Zhenfeng Duan, Detao Yin, Yubing Zhou. Front Oncol 2021
0

Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
Shuang Liu, Tom Cadoux-Hudson, Christopher J Schofield. Curr Opin Chem Biol 2020
9

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.
Xiaoyan Liu, Yuping Gong. Biomark Res 2019
30

Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling.
Zoltán N Oltvai, Susan E Harley, David Koes, Stephen Michel, Erica D Warlick, Andrew C Nelson, Sophia Yohe, Pawel Mroz. Cold Spring Harb Mol Case Stud 2021
1

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.
Justin S Becker, Amir T Fathi. Curr Cancer Drug Targets 2020
6

Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis.
Feng Shi, Ya He, Jiangjiang Li, Min Tang, Yueshuo Li, Longlong Xie, Lin Zhao, Jianmin Hu, Xiangjian Luo, Min Zhou,[...]. Mol Metab 2020
5